All News

With the federal government continuing its reconsideration of vaccine guidelines in the US, Jeff Goad, PharmD, MPH, explains what it means for community pharmacies.

In a reversal of its refusal-to-file letter issued last week, the FDA decides to move forward with Moderna’s mRNA flu vaccine developments.

Amid common patient threats stemming from severe hypoglycemia, researchers explore how proactive pharmacist outreach can translate to safer prescribing regimens for patients with diabetes.

In this episode, Natalie DiPietro Mager, PharmD, PhD, MPH, chats with Laney Poye, the director of marketing and communications at the Preeclampsia Foundation.

Jeff Goad, PharmD, MPH, joins Drug Topics to discuss potential COVID-19 vaccine removal and what it could mean for the future of mRNA vaccine technology.

Duvakitug TL1A antibody sustains remission and endoscopic response for 44 weeks in ulcerative colitis and Crohn disease, supporting phase 3 momentum.

The FDA approves pitolisant for pediatric cataplexy, offering a rare noncontrolled narcolepsy option with real-world safety data and key interaction tips.

Positive phase 3 data from its KALOS and LOGOS trials show the efficacy and safety of Breztri compared with 2 additional therapies.

Through a mathematical model used to assess asthma dynamics, researchers explore how active smoking can impact disease outcomes.

With expanding scopes of practice, there has never been a better time to introduce or expand clinical services that improve patient outcomes.

Tennessee’s 2024 expansion of pharmacist's scope of practice authorizes independent prescribing and test-and-treat services, positioning pharmacists as primary care extenders in underserved communities.

Understanding acceptable thresholds helps prevent unnecessary discontinuation of guideline-directed therapy.

In a move that comes as a surprise to Moderna and various vaccine experts, the FDA continues its skeptic exploration of mRNA vaccine technology.

Amid evolving standards of care in the management of diabetes, researchers explore the role of pharmacists in facilitating continuous glucose monitoring education.

Direct contracting can boost transparent drug pricing and help independent pharmacies earn fairly while patients save on generic medications.

The decision removes risk statements regarding cardiovascular disease, breast cancer, and probable dementia from the boxed warning.

As the pharmacy industry seemingly transforms in real-time, expert pharmacists and digital health experts explain how DTP models are paving a new path for drug distribution.

In their continued fight against major health care corporations, Senators Elizabeth Warren and Josh Hawley are aiming to delink ownership among PBMs, insurers, and wholesalers.

Buchanan Ingersoll & Rooney’s Dae Lee, PharmD, Esq, CPBS, and Lucas Morgan, Esq, provide a timely legal update regarding GLP-1 distribution and compounding.

As shrinking dispensing margins make it harder for pharmacies to keep their doors open on prescriptions alone, many are turning to clinical services as a lifeline.

GLP-1 therapies lower C-reactive protein and tumor necrosis factor-alpha, signaling cardiovascular protection; pharmacists tackle cost

Acoltremon ophthalmic solution effectively increases tear production for dry eye disease, demonstrating benefits and a favorable safety profile in clinical trials.

Timothy Aungst, PharmD; Ravi Patel, PharmD, MBA, MS; and Smit Patel, PharmD; provided much-needed nuance to the evolving nature of DTP pharmacy models in today’s landscape.

Phase 3 OCEANIC-STROKE shows asundexian cuts recurrent ischemic stroke by 26% on top of antiplatelets, without more major bleeding.

In what reports are calling a landmark settlement, Cigna agrees to make good on years of unfair business dealings that have affected patients and independent pharmacies.

Exploring the perspectives of health care professionals, researchers test the feasibility of the Asthma Care from Home project.

Pharmacists guide smokers in choosing effective OTC cessation aids, enhancing success rates with tailored nicotine replacement therapies for cravings and withdrawal relief.

Real-world data shows empagliflozin cuts mortality in broader type 2 diabetes patients, supporting wider sodium-glucose co-transporter 2 inhibitor use with careful safety monitoring.